Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antiviral therapeutics - SIGA

Drug Profile

Research programme: antiviral therapeutics - SIGA

Alternative Names: ST-148; ST-193; ST-294; ST-383; ST-610; ST-669

Latest Information Update: 23 Sep 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SIGA Technologies
  • Class Benzimidazoles; Small molecules
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Bunyavirus infections; Dengue; Ebola virus infections; Junin virus infections; Lassa fever; Marburg virus disease; Viral infections

Most Recent Events

  • 24 Aug 2011 SIGA technologies receives grant from National Institutes of Health (NIH) for antiviral drug development in Lassa fever and other haemorrhagic fevers of Arenavirus origin
  • 25 Feb 2010 SIGA Technologies receives funding from the US Department of Defense for ST 669 development in Viral infections
  • 25 Feb 2010 Preclinical trials in Viral infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top